Review Article

Shexiang Baoxin Pill for Acute Myocardial Infarction: Clinical Evidence and Molecular Mechanism of Antioxidative Stress

Table 2

Basic information of the included randomized controlled trials.

IDSample size (T/C)Mean age (years)Diagnostic criteriaInterventionComparisonDuration of treatmentOutcomes

Chen ZH 2013105 (50/55)T:
C:
ISBP plus RTRT8 weeks②④⑤⑥
Luo Y C 201580 (40/40)T:
C:
IISBP plus RTRT4 weeks
Ge R L 201570 (35/35)T:
C:
ISBP plus RTRT8 weeks②⑤⑥
Yang G L 2013120 (60/60)T:
C:
IISBP plus RTRT24 weeks②④⑧
Ma C 202090 (45/45)T:
C:
Compliant with IISBP plus RTRT2 weeks①②⑤⑦⑧
Tian F Q 201664 (32/32)T:
C:
IISBP plus RTRT2 weeks①③④⑧
Wang S S 2016106 (53/53)T:
C:
Compliant with IISBP plus RTRT2 weeks①②⑤⑦
Bai X 202082 (41/41)T:
C:
Compliant with IISBP plus RTRT2 weeks②⑤⑧
Wei L N 201896 (48/48)T:
C:
Compliant with IISBP plus RTRT2 weeks①②⑤⑦⑧
Jiang F J 202060 (30/30)T:
C:
Compliant with IISBP plus RTRT2 weeks①⑧
Zhang X T 2017140 (70/70)T:
C:
Compliant with IISBP plus RTRTNR①⑧
Xu J 201790 (45/45)T:
C:
IIISBP plus RTRT12 weeks②⑥
Yang F 2015120 (60/60)T:
C:
Compliant with IISBP plus RTRT10 weeks①③④⑧
Feng B 202083 (43/40)T:
C:
IISBP plus RTRT2 weeks③④
Huang P D 201688 (44/44)T:
C:
IISBP plus RT plus PCIRT plus PCI8 weeks①②③④⑤⑥
Jiang D J 202080 (40/40)T:
C:
Compliant with IISBP plus RT plus PCIRT plus PCI2 weeks②⑦
Xu F L 2018200 (100/100)T:
C:
Compliant with IISBP plus RT plus PCIRT plus PCI12 weeks⑤⑥⑧
Lin G Q 201059 (30/29)T:
C:
Compliant with IISBP plus RT plus PCIRT plus PCI24 weeks①②④⑤
Ma R J 2019116 (60/56)T:
C:
Compliant with IISBP plus RT plus PCIRT plus PCI4 weeks②④⑧

Note: T: treatment group; C: control group; SBP: Shexiang Baoxin Pill; RT: routine treatment (including oxygen inhalation, vascular dilation, anticoagulation, and thrombolysis); PCI: percutaneous coronary intervention; CPGs: clinical practice guidelines; NR: not reported; I: diagnostic criteria of AMI developed by the World Health Organization; II: diagnostic criteria of AMI developed by the Chinese Cardiovascular Society; III: diagnostic criteria of AMI developed by the American Heart Association and American College of Cardiology; ①: clinical efficacy rate; ②: cardiac function; ③: oxidative stress; ④: AMI evaluation index; ⑤: inflammatory factors; ⑥: blood lipid level; ⑦: vascular endothelial function; ⑧: complication rate.